Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Lum002
2. Shp626
1. 1025216-57-2
2. Sar-548304 Free Acid
3. X2jz0451h8
4. N-(3-o-benzyl-6-o-sulfo-beta-d-glucopyranosyl)-n'-{3-[(3s,4r,5r)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1h-1lambda6-benzothiepin-5-yl]phenyl}urea
5. Volixibat [usan:inn]
6. Unii-x2jz0451h8
7. Starbld0000127
8. Volixibat [inn]
9. Volixibat [usan]
10. Volixibat [who-dd]
11. Chembl3707222
12. Schembl12196537
13. Dtxsid001098929
14. Db13914
15. Urea, N-(3-((3s,4r,5r)-3-butyl-7-(dimethylamino)-3-ethyl-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenyl)-n'-(3-o-(phenylmethyl)-6-o-sulfo-beta-d-glucopyranosyl)-
16. Hy-101190
17. Cs-0020958
18. Q27293432
19. [(2r,3r,4s,5r,6r)-6-[[3-[(3s,4r,5r)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-4,5-dihydro-2h-1lambda6-benzothiepin-5-yl]phenyl]carbamoylamino]-3,5-dihydroxy-4-phenylmethoxyoxan-2-yl]methyl Hydrogen Sulfate
20. N-[3-[(3s,4r,5r)-3-butyl-7-(dimethylamino)-3-ethyl-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenyl]-n'-[3-o-(phenylmethyl)-6-o-sulfo-beta-d-glucopyranosyl]urea
21. Urea, N-(3-((3s,4r,5r)-3-butyl-7-(dimethylamino)-3-ethyl-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl)phenyl)-n'-(3-o-(phenylmethyl)-6-o-sulfo-.beta.-d-glucopyranosyl)-
| Molecular Weight | 806.0 g/mol |
|---|---|
| Molecular Formula | C38H51N3O12S2 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 14 |
| Exact Mass | 805.29141642 g/mol |
| Monoisotopic Mass | 805.29141642 g/mol |
| Topological Polar Surface Area | 238 Ų |
| Heavy Atom Count | 55 |
| Formal Charge | 0 |
| Complexity | 1450 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Volixibat is an investigational drug that has not been approved for use in any conditions.
Lipid Regulating Agents
Substances that alter the metabolism of LIPIDS. (See all compounds classified as Lipid Regulating Agents.)
Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum. ASBT is primarily responsible for the recirculation of bile acids and therefore for hepatic lipid and glucose metabolism. Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in the liver have been implicated in its pathogenesis.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Volixibat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Volixibat, including repackagers and relabelers. The FDA regulates Volixibat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Volixibat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Volixibat supplier is an individual or a company that provides Volixibat active pharmaceutical ingredient (API) or Volixibat finished formulations upon request. The Volixibat suppliers may include Volixibat API manufacturers, exporters, distributors and traders.
Volixibat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Volixibat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Volixibat GMP manufacturer or Volixibat GMP API supplier for your needs.
A Volixibat CoA (Certificate of Analysis) is a formal document that attests to Volixibat's compliance with Volixibat specifications and serves as a tool for batch-level quality control.
Volixibat CoA mostly includes findings from lab analyses of a specific batch. For each Volixibat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Volixibat may be tested according to a variety of international standards, such as European Pharmacopoeia (Volixibat EP), Volixibat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Volixibat USP).
LOOKING FOR A SUPPLIER?
